



Presidential Vision – Emile Voest

Candidate Name: Emile Voest

Institute: Netherlands Cancer Institute, Amsterdam

Country: The Netherlands

Presidential Mission

“Creating value for patients by providing our ESMO members with knowledge, by fighting inequality in cancer care and access to medication, and by facilitating strong oncological leadership on the (inter)national level”

Presidential Vision and Programme

If elected as President I would like to contribute to ESMO on three levels:

1. Education: ESMO has a strong reputation in disseminating knowledge, whether this involves new developments with potential future impact or providing members with comprehensive overviews of existing knowledge. Where precision medicine in oncology aims to find the right treatment for the right patients, ESMO should expand on a precision education program which brings tailor made programs to the various regions of our global society. Future challenges of ESMO’s educational program include open source publishing, the use of artificial intelligence in developing guide lines, novel ways on how oncologists, pharma and scientists want to share their data and creating virtual educational spaces.
2. Innovation: ESMO has not yet profiled itself by performing independent research. This is a strategic question and my ambition would be to have a limited number of scientific projects under the direct supervision of ESMO. This has several advantages; 1. It will help to establish a scientific foundation for specific strategic aims that ESMO may have at that time. Examples may be artificial intelligence in developing guidelines, developing procedures for data sharing across hospitals, investing in registries, refining methodologies to support e.g. ESMO-MCBS, generating evidence underlying specific policy areas, and more. Making this strategic choice to invest in research will not only make ESMO an even stronger player but also broaden the financial basis of ESMO.
3. Policy: ESMO’s presence in Brussel is increasingly important, not only to make sure that cancer is and remains part of the EU mission but also to battle inequality in care across and beyond Europe. ESMO will also need to regularly revisit their position on expensive medication, biosimilars, reimbursement procedures. It will be important that ESMO serves as a trusted third party for the EU. This requires a clear strategy towards our involvement with industry. Similar arguments are true for ESMO’s global interactions with WHO.



My potential value and experience to ESMO in the three areas described above may be reflected by my curriculum vitae. In summary I will describe specific contributions.

Ad Education: throughout my career I have been involved in teaching. This included the foundation of a graduate school for translation oncology at the University Medical Center Utrecht which serves a clear purpose in bridging the clinic and preclinical science. In 2019 the graduate school will celebrate its 10th birthday with >hundred PhD students graduating.

As a professor of Medical Oncology I have supervised and taught courses in the curriculum of the Medical School and personally supervised PhD students (>40). At the NKI I have boosted the AVL Academy to support all levels of education. At the congress level, I have been involved in the organisation and scientific committees of several international meetings.

Ad Innovation: I became a medical oncologist to make a difference in the lives of cancer patients. Maintaining the status quo is not my ambition. My research/innovation activities are reflected by my publications ranging from ethical questions to basic research questions. Most of my work is through team science, I do not think that working in isolation will help translation research. During my career I have established various not-for-profit foundations (Center for Personalized Cancer Treatment, HUB for Organoid Technology, Hartwig Medical Foundation) which now serve a clear purpose in precision medicine. I recently was inaugurated in the prestigious Oncode Institute, a virtual institute supported by the government and Dutch Cancer Society, to bring new research findings to patients.

Ad Policy: There are various levels of policy making and I have contributed to some areas. As Executive Medical Director I am a sounding board for the government and other regulatory bodies. Recently, I have been the architect of a pay for performance model for approved drugs but used outside their label. This model is now embraced by the Dutch Health Authorities and Payers. It addresses access to approved drugs for patients with rare cancers (profiles) in the absence of randomised clinical trials. Another policy that has received significant attention is to implement whole genome sequencing in daily practice in the Netherlands. On a more international level I serve on the ESMO board and on the board of Cancer Core Europe to build a clear strategy to advance cancer policies.



Comprehensive list of current and past positions within ESMO

- ESMO Executive Board Member (2015-2018)
- ESMO Council Member (2019-now)
- Chair of the Audit Committee (2015-2018)
- Treasurer (2015-2018)
- Scientific Chair of ESMO Asia 2017
- Chair of the Publishing Committee (2019-now)
- Editorial Board of ESMO Open (2017-now)

Comprehensive list of current and past positions as an employee, officer or in a body of a company, society, foundation, charity or organisation, paid or not, outside ESMO

Current Positions:

- | | |
|-------|--|
| 1999- | Professor of Medical Oncology, University of Utrecht, University Medical Center, Utrecht |
| 2010- | Chair of the Scientific Advisory Board of InteRNA |
| 2013- | Editorial board of Clinical Cancer Research |
| 2014- | Medical Director, Executive Board of Directors, Netherlands Cancer Institute |
| 2014- | Board member of the Center for Personalized Cancer Treatment |
| 2014- | Board member of Biomed NKI AVL |
| 2014- | Board member of AVL foundation |
| 2014- | Board member of Biotherapeutics Unit (AmBTU) |
| 2014- | Supervisory Board member Netherlands Laboratory or Anticancer Drug Formulation |
| 2015- | Member of the Scientific Audit Committee of the EORTC |
| 2015- | Editorial board of JAMA Oncology |
| 2015- | Member of supervisory board Hartwig Medical Foundation |
| 2016- | Executive Board member Cancer Core Europe |

Past Positions:

- | | |
|-----------|---|
| 1994-1995 | Fellowship Dutch Cancer Society |
| 1996-1998 | Staff member department of Medical Oncology, University Hospital Utrecht, The Netherlands |
| 1996-2003 | Head of the Laboratory of Medical Oncology, University Hospital Utrecht |
| 1998-1999 | Acting head of the department of Medical Oncology, University Medical Center Utrecht |
| 1998-2004 | Member of the Internal Medicine Steering Committee |



1999-2005	Co-director of the research institute "Developmental biology and Oncology", University Medical Center, Utrecht
1999-2014	Head Department of Medical Oncology
1999-2002	Editorial board of "Kanker", journal of the Dutch Cancer Society
1999-2005	Co-director of Research Institute "Genes" at the University Medical Center
2000-2008	Chair Scientific Evaluation Committee for Individual Grants University Medical Center Utrecht
2000-2004	Member of the scientific committee of the Dutch Internal Medicine Conference
2001	Editor of "Tumor angiogenesis and microcirculation", MDI Publishers New York
2001-2005	Board member of the Royal Academy of Sciences Graduate School of Developmental Biology
2001-2006	Board Member Graduate School of Developmental Biology
2002-2006	Member of the commission to stimulate research of the Comprehensive Cancer Center Central Netherlands
2002-2006	Member of the Scientific Advisory Board of "Primagen" (2002-2006)
2002-2008	Member of the Committee of Clinical Applied Research of the Dutch Cancer Society
2002-2010	Member of the Scientific Advisory Board of the "Vanderes Foundation"
2005-2010	Director of the Oncology Research Program UMC Utrecht
2005-2006	Member of the Scientific Advisory Board of ABN Amro Life Sciences Capital
2005-2010	Member of the Scientific Advisory Board of Forbion Capital
2005-2011	Member of the Committee of Translational Research of the Dutch Cancer Society
2006-2010	Chair of the Oncology Research Program of the UMC Utrecht
2006-2010	Member of the Academic Biomedical Cluster Committee "High potentials"
2006-2011	Editor of the "Angiogenese Journaal"
2007-2009	Board Member of the Graduate School of Life Sciences
2007-2010	Director of Cancer Research Program of the UMC Utrecht Cancer Center
2007-2013	Board member of the Dutch Working Party on Immunology-Oncology
2007-2012	Member of the scientific committee of the Dutch/Belgian Medical Oncology Conference
2008-2011	Member of the Scientific Board of the Dutch Cancer Society
2009-2011	Chairman of the yearly course "Angiogenesis: a key target in oncology"



2010-2013	Founder and Director of PhD program “Clinical and Translational Oncology” of the Graduate School of Life Sciences 2011-2014 Chair of the Scientific Advisory Board of the Dutch Cancer Society
2011	Member Educational Committee ASCO
2011	Member Educational Committee AACR
2011-2013	Manager Research and Education, Division of Internal Medicine and Dermatology, UMC Utrecht.
2012-2014	Chair of the Scientific Advisory Board of the Pediatric Oncology Foundation “KiKa”
2012-2013	Chair CRC ASCO subcommittee “Meaningful endpoints of clinical trials”
2013-2014	Medical Manager Medical Oncology Disciplines, UMC Utrecht in preparation of merger with NKI.
2013	Co-chair of the joint scientific advisory board of SU2C-AACR and SU2C-KWF
2010-2014	Founder and chair of the Center for Personalized Cancer Treatment
2008-2015	Member of the scientific advisory board of Targeted Anti-tumor Therapy Congress
2012-2017	Member of the Cancer Research Committee (CRC) American Society of Clinical Oncology (ASCO)
2013-2016	Medical Director of the Hub Foundation for OrganoidTechnology (established September 26, 2013).
2015-2016	Chair ASCO Cancer Research Committee
2017	Member Scientific Program Committee of the EACR-OECI Conference on Precision Medicine for Cancer (March 2017)